DE69942031D1 - In prostatakrebs exprimiertes gen - Google Patents

In prostatakrebs exprimiertes gen

Info

Publication number
DE69942031D1
DE69942031D1 DE69942031T DE69942031T DE69942031D1 DE 69942031 D1 DE69942031 D1 DE 69942031D1 DE 69942031 T DE69942031 T DE 69942031T DE 69942031 T DE69942031 T DE 69942031T DE 69942031 D1 DE69942031 D1 DE 69942031D1
Authority
DE
Germany
Prior art keywords
prostate cancer
gene
expressed
prostate
gen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942031T
Other languages
English (en)
Inventor
Daniel E Afar
Rene S Hubert
Stephen Chappell Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of DE69942031D1 publication Critical patent/DE69942031D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/91—Strengthening cell or tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69942031T 1998-09-30 1999-09-30 In prostatakrebs exprimiertes gen Expired - Lifetime DE69942031D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10257298P 1998-09-30 1998-09-30
US14658499P 1999-07-28 1999-07-28
PCT/US1999/023005 WO2000018925A1 (en) 1998-09-30 1999-09-30 Gene expressed in prostate cancer

Publications (1)

Publication Number Publication Date
DE69942031D1 true DE69942031D1 (de) 2010-04-01

Family

ID=26799520

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942031T Expired - Lifetime DE69942031D1 (de) 1998-09-30 1999-09-30 In prostatakrebs exprimiertes gen

Country Status (12)

Country Link
US (4) US6509458B1 (de)
EP (2) EP1117783B1 (de)
AT (1) ATE458049T1 (de)
AU (2) AU764096B2 (de)
CA (1) CA2344620A1 (de)
CY (1) CY1110029T1 (de)
DE (1) DE69942031D1 (de)
DK (2) DK2182064T3 (de)
ES (1) ES2339726T3 (de)
IL (2) IL142194A0 (de)
PT (1) PT1117783E (de)
WO (1) WO2000018925A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2339726T3 (es) 1998-09-30 2010-05-24 Agensys, Inc. Gen expresado en el cancer de protata.
WO2000071711A2 (en) * 1999-05-20 2000-11-30 Fahri Saatcioglu Differentially expressed genes in prostate cancer
US7189565B2 (en) * 2001-03-23 2007-03-13 Fahri Saatcioglu Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7611892B2 (en) * 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2003085378A2 (en) * 2002-04-03 2003-10-16 Syngenta Participations Ag Detection of wheat and barley fungal pathogens which are resistant to certain fungicides using the polymerase chain reaction
JP2004048317A (ja) * 2002-07-11 2004-02-12 Pioneer Electronic Corp ノイズ抑圧機能付きデジタル放送受信機
US7192709B2 (en) * 2004-03-15 2007-03-20 Digigenomics Co., Ltd. Methods for identification, assessment, prevention, and therapy of cancer
WO2009048681A2 (en) * 2007-08-06 2009-04-16 The Regents Of The University Of California Methods of tissue-based diagnosis
US9814422B2 (en) 2007-08-06 2017-11-14 The Regents Of The University Of California Compositions for solubilizing cells and/or tissue
US8609041B2 (en) 2007-08-06 2013-12-17 Samir Mitragotri Apparatus for solubilizing tissue
US8389582B2 (en) 2007-08-06 2013-03-05 Samir Mitragotri Composition for solubilizing tissue comprising 3-(decyl dimethyl ammonio) propane sulfonate and tetraethylene glycol dodecyl ether
US8642664B2 (en) 2007-08-06 2014-02-04 Samir Mitragotri Composition for solubilizing tissue and cells comprising N-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate and polyoxyethylene (10) cetyl ether
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US8968210B2 (en) * 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
CN104655828B (zh) 2009-02-13 2018-04-27 加州大学评议会 基于组织的诊断的系统、方法和装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018730A1 (en) * 1994-12-15 1996-06-20 Human Genome Sciences, Inc. Prostatic growth factor
US5912143A (en) * 1996-12-27 1999-06-15 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a human mage protein homolog
EP0981541B1 (de) * 1997-03-10 2004-06-02 The Regents Of The University Of California Prostata stammzell-antigen (psca)
WO1998058943A1 (en) * 1997-06-20 1998-12-30 Human Genome Sciences, Inc. Borrelia burgdorferi polynucleotides and sequences
US5922546A (en) 1997-08-25 1999-07-13 Smithkline Beecham Corporation Human disintegrin metalloprotease KUZ gene
AU4839999A (en) * 1998-06-29 2000-01-17 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
ES2339726T3 (es) 1998-09-30 2010-05-24 Agensys, Inc. Gen expresado en el cancer de protata.
US7368527B2 (en) * 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
AU4074400A (en) 1999-04-09 2000-11-14 Human Genome Sciences, Inc. 49 human secreted proteins
US20020168638A1 (en) 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer

Also Published As

Publication number Publication date
ES2339726T3 (es) 2010-05-24
EP1117783A1 (de) 2001-07-25
PT1117783E (pt) 2010-04-15
US7803916B2 (en) 2010-09-28
US7968283B2 (en) 2011-06-28
DK2182064T3 (da) 2012-12-17
IL142194A (en) 2010-12-30
DK1117783T3 (da) 2010-05-17
WO2000018925A1 (en) 2000-04-06
ATE458049T1 (de) 2010-03-15
US20030211520A1 (en) 2003-11-13
EP2182064B1 (de) 2012-08-29
AU2003259622B2 (en) 2006-07-06
CY1110029T1 (el) 2015-01-14
AU764096B2 (en) 2003-08-07
US6509458B1 (en) 2003-01-21
CA2344620A1 (en) 2000-04-06
IL142194A0 (en) 2002-03-10
EP2182064A1 (de) 2010-05-05
US7432346B2 (en) 2008-10-07
EP1117783B1 (de) 2010-02-17
AU2003259622A1 (en) 2003-11-20
AU6285599A (en) 2000-04-17
US20100303845A1 (en) 2010-12-02
US20090098629A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
ATE458049T1 (de) In prostatakrebs exprimiertes gen
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
DE60041333D1 (de) Hen prostatkrebs exprimiert wird, und deren verwendungen
HK1203568A1 (en) Gene expression profiling in biopsied tumor tissues
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
NO20010196L (no) Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft
DE69735643D1 (de) IL12 zur Gentherapie der Tumoren
GR3036047T3 (en) Inherited and somatic mutations of apc gene in colorectal cancer of humans.
DK1109021T3 (da) Snail, en ny tumoral progressionsmarkör og et targetprotein for nye antitumorale forbindelser
EP1175616A4 (de) Verfahren für die diagnose und die behandlung von metastatischen prostatatumoren
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
DK1135513T4 (da) Adenovirus-medieret genterapi
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
WO2002008456A8 (de) Verfahren zur identifizierung metastasierender tumorzellen
WO2002085286A3 (en) Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
WO2001079505A3 (en) INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY
AU2002243918A1 (en) Methods for the treatment and diagnosis of prostate cancer based on p75ntr tumor
AU2003282069A8 (en) Tumor marker proteins for diagnosis and therapy of cancer and cancer risk assessment

Legal Events

Date Code Title Description
8364 No opposition during term of opposition